Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07213648 · ClinicalTrials.gov registry record · NA
Modification of Threat Interpretation Bias to Reduce Anxiety in Neurodegenerative Movement Disorders (Aim 3)
A NA study of Parkinson Disease and Huntington Disease, sponsored by University of Virginia.
- Recruiting
- Registry status
- NA
- Development phase
- 136
- Enrollment target
- 1
- Study location
NCT07213648: Recruiting NA study of Parkinson Disease and Huntington Disease, sponsored by University of Virginia.
NCT07213648 is a NA study of Parkinson Disease and Huntington Disease that is actively recruiting participants, run by University of Virginia. The registered enrollment target is 136 participants, below the 5,326-participant average among 297 other Parkinson Disease trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07213648, a NA study of Parkinson Disease and Huntington Disease, is actively recruiting participants, sponsored by University of Virginia.
- RECRUITING
- Registry status
- NA
- Development phase
- 136 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to assess preliminary efficacy of a tailored cognitive bias modification for interpretation (CBM-I) app for reducing anxiety in Huntington's disease and Parkinson's disease.
Primary Outcome
Patient-reported anxiety symptoms will be measured using the Quality of Life in Neurological Disorders Anxiety short form (NeuroQoL-Anxiety) total raw scores. This measure includes 8 items ranked 1-5, where the total score is the sum of item scores (range 8-40), and higher scores indicate worse anxiety symptoms.
Conditions Studied
Interventions
- BEHAVIORAL MindTrails-Movement
- OTHER Waitlist Control
Study Locations (1)
Virginia
- Univeristy of Virginia School of Nursing - Charlottesville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 136 participants |
| Start Date | 2025-11-20 |
| Est. Completion | 2026-09 |
| Phase | NA |
What NCT07213648 shows while recruiting
NCT07213648 is an interventional study that assigns participants to a tested intervention. The registered 136 participants enrollment target is mid-sized for trials with a published cap, below the 5,326-participant average among 297 other Parkinson Disease trials with a reported enrollment target (97% lower).
The record links to 2 conditions, with Parkinson Disease appearing as the primary indexed condition, and to 2 interventions - of which MindTrails-Movement is the first listed.
NCT07213648 reports a single indexed study location in Virginia.
Frequently Asked Questions
What is clinical trial NCT07213648 about?
NCT07213648 is a clinical study titled "Modification of Threat Interpretation Bias to Reduce Anxiety in Neurodegenerative Movement Disorders (Aim 3)". The purpose of this study is to assess preliminary efficacy of a tailored cognitive bias modification for interpretation (CBM-I) app for reducing anxiety in Huntington's disease and Parkinson's disease.
What is the current status of trial NCT07213648?
This trial is currently recruiting. It is a NA study. The enrollment target is 136 participants. The study started on 2025-11-20. Estimated completion is 2026-09.
What conditions does trial NCT07213648 study?
This clinical trial studies the following conditions: Parkinson Disease, Huntington Disease.
What interventions are being tested in trial NCT07213648?
The interventions under investigation include: MindTrails-Movement (BEHAVIORAL), Waitlist Control (OTHER).
Who is sponsoring clinical trial NCT07213648?
This trial is sponsored by University of Virginia, which has 449 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07213648 being conducted?
This trial has 1 study location across Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Parkinson Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07213648's enrollment target sits among peer trials
136 60th of 297 higher than 238 of 297 other Parkinson Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Parkinson Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Evaluation of Correlation Between Oculometric Measures and Clinical Assessment in Parkinson's Disease
RECRUITING · NA
-
Neocortical Microarchitecture of Executive Function
RECRUITING · NA
-
Neurophysiology of Reward Signaling in Parkinson's Disease
RECRUITING · NA
-
Balance Tele-Rehab in Parkinson's Disease Parkinson's Disease
RECRUITING · NA
-
Rock Steady Boxing: A Community Based In Person Class
RECRUITING · NA
-
Corticostriatal Contributions to Parkinson's Disease Cognitive Impairment
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01555892 · 136 participants · Phase 1
Cytotoxic T-Lymphocytes for EBV-positive Lymphoma, GRALE
- NCT03216525 · 136 participants · Phase 3
Alvimopan Versus Placebo in Patients Undergoing Radical Cystectomy on an Enhanced Recovery Protocol
- NCT04476901 · 136 participants · Phase 2
Administration of Allogeneic-MSC in Patients With Non-Ischemic Dilated Cardiomyopathy
- NCT04603898 · 136 participants · NA
Oxalate Formation From Ascorbic Acid
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI